恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

cripto-ag捕鱼平台

文字: 2019-9-24    浏览次数:378    

abstract

cripto-1 may act as an independent predictor for prognosis in hepatocellular carcinoma (hcc). however, the function of cripto-1 in hcc cells and its response to postoperative transarterial chemoembolization (tace) in hcc patients remains unclearly.

cripto-1可作为肝细胞癌(hcc)预后的独立预测因子。然而,cripto-1hcc细胞中的功能及其对hcc患者术后经动脉化疗栓塞(tace)的作用尚不清楚。

 

up-regulated cripto-1 expression boosted the ability of cell proliferation, migration and invasion in hcc cells in vitro. while opposite results were observed in hcc cells with down-regulated cripto-1 expression. cripto-1 expression was correlated with epithelial-mesenchymal transition (emt) relevant biomarkers. furthermore, in high cripto-1 expression patients, those with adjuvant tace had favorable ttr and os times. on contrary, adjuvant tace may promote tumor recurrence but had no influence on os time in patients with low cripto-1 expression. in different subgroups of vascular invasion, larger tumor size or liver cirrhosis, patients with adjuvant tace had longer ttr and os times than those without tace in patients with high cripto-1 expression, while they could not obtain benefits from adjuvant tace in patients with low-expressed cripto-1 expression.

体外实验显示,cripto-1表达的上调增强了hcc细胞的增殖、迁移和侵袭力。而hcc细胞中cripto-1表达下调的结果则相反。cripto-1表达与上皮细胞间质转化(emt)相关生物标志物相关。此外,在高cripto-1表达的患者中,辅助tace的患者具有较好的ttros。相反,辅助tace则可能会促使肿瘤复发,但对低cripto-1表达患者的os没有影响。在血管浸润、肿瘤大小或肝硬程度化不同的亚组中,高cripto-1表达患者辅助tace治疗后ttros较未行tace的患者长,而低cripto-1表达患者辅助tace并无获益。

 

in conclusion, cripto-1 may be a potential prognostic factor in predicting outcome of hcc patients with tace therapy, and combined with cripto-1 and tumor features may be helpful to stratify patients with respect to prognosis and response to adjuvant tace.

综上所述,cripto-1可能是预测hcc患者接受tace治疗后预后的潜在因素,cripto-1和肿瘤特征相结合可能有助于根据患者的预后和对辅助tace的反应对患者进行分层。